专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110014213A1 HUMAN ANTI-ALPHA 9 INTEGRIN ANTIBODY 有权
标题翻译：人类抗ALPHA 9整合抗体
公开(公告)号：US20110014213A1
公开(公告)日：2011-01-20
申请号：US12810939
申请日：2008-12-26
申请人： Masaharu Torikai , Daisuke Ishikawa , Toshihiro Nakashima , Hirofumi Higuchi , Fumihiko Sakai , Nobuchika Yamamoto , Hirotada Fujita , Katsunari Taguchi
发明人： Masaharu Torikai , Daisuke Ishikawa , Toshihiro Nakashima , Hirofumi Higuchi , Fumihiko Sakai , Nobuchika Yamamoto , Hirotada Fujita , Katsunari Taguchi
IPC分类号： A61K39/395 , C07K16/28 , C07H21/04 , C12N15/63 , C12N5/10 , C12P21/02 , A61P19/02
CPC分类号： C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/52 , C07K2317/622 , C07K2317/92 , C07K2319/00
摘要： The present invention provides a human anti-α9 integrin antibody or an antibody fragment which specifically recognize human α9 integrin and mouse α9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse α9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-α9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.
摘要翻译：本发明提供一种人抗α9整联蛋白抗体或特异性识别人α9整联蛋白和小鼠α9整联蛋白的抗体片段，抑制与其配体的相互作用，特别是识别人和小鼠α9整联蛋白环区的抗体或抗体片段，编码抗体或抗体片段的基因，含有该基因的重组表达载体，携带该基因的转化体，使用该转化体的人抗α9整联蛋白抗体的制备方法或抗体片段，以及预防或治疗类风湿性关节炎其含有抗体或抗体片段。

2. 发明授权

US08715655B2 Human anti-α9 integrin antibody 有权
标题翻译：人抗α9整联蛋白抗体
公开(公告)号：US08715655B2
公开(公告)日：2014-05-06
申请号：US12810939
申请日：2008-12-26
申请人： Masaharu Torikai , Daisuke Ishikawa , Toshihiro Nakashima , Hirofumi Higuchi , Fumihiko Sakai , Nobuchika Yamamoto , Hirotada Fujita , Katsunari Taguchi
发明人： Masaharu Torikai , Daisuke Ishikawa , Toshihiro Nakashima , Hirofumi Higuchi , Fumihiko Sakai , Nobuchika Yamamoto , Hirotada Fujita , Katsunari Taguchi
IPC分类号： A61K39/395 , C07K16/00 , C07K16/46 , C07K16/28 , G01N33/53
CPC分类号： C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/52 , C07K2317/622 , C07K2317/92 , C07K2319/00
摘要： The present invention provides a human anti-α9 integrin antibody or an antibody fragment which specifically recognize human α9 integrin and mouse α9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse α9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-α9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.
摘要翻译：本发明提供一种人抗α9整联蛋白抗体或特异性识别人α9整联蛋白和小鼠α9整联蛋白的抗体片段，抑制与其配体的相互作用，特别是识别人和小鼠α9整联蛋白环区的抗体或抗体片段，编码抗体或抗体片段的基因，含有该基因的重组表达载体，携带该基因的转化体，使用该转化体的人抗-α9整联蛋白抗体的制备方法或抗体片段，以及预防或治疗类风湿性关节炎其含有抗体或抗体片段。

3. 发明授权

US08603476B2 Humanized anti-human α9-integrin antibody 有权
标题翻译：人源化抗人α9整联蛋白抗体
公开(公告)号：US08603476B2
公开(公告)日：2013-12-10
申请号：US12812341
申请日：2009-01-09
申请人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
发明人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
IPC分类号： A61K39/395
CPC分类号： C07K16/2839 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human α9 integrin in the pathogenesis, which uses the antibody.
摘要翻译：本发明提供与供体小鼠抗人α9整联蛋白抗体相比具有改善的活性和/或性质的人源化抗人α9整联蛋白抗体，即包含重链可变区的人源化抗人α9整联蛋白抗体，其包含的SEQ ID NO：11所示的氨基酸序列和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，含有重链可变区的人源化抗人α9整联蛋白抗体包含由由SEQ ID NO：13所示的氨基酸序列和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，含有重链可变区的人源化抗人α9整联蛋白抗体由SEQ ID NO：15所示的氨基酸序列和由SEQ ID NO：9所示的氨基酸序列组成的轻链可变区，以及预防或治疗涉及人类α9整联蛋白在发病机制中使用抗体。

4. 发明申请

US20110059077A1 HUMANIZED ANTI-HUMAN ALPHA 9-INTEGRIN ANTIBODY 有权
标题翻译：人类抗人ALPHA 9整合抗体
公开(公告)号：US20110059077A1
公开(公告)日：2011-03-10
申请号：US12812341
申请日：2009-01-09
申请人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
发明人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
IPC分类号： C07K16/28 , C12N15/13 , C12N15/70 , C12N1/21 , C12P21/08 , A61K39/395
CPC分类号： C07K16/2839 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human α9 integrin in the pathogenesis, which uses the antibody.
摘要翻译：本发明提供与供体小鼠抗人α9整联蛋白抗体相比具有改善的活性和/或性质的人源化抗人α9整联蛋白抗体，即包含重链可变区的人源化抗人α9整联蛋白抗体，其包含的SEQ ID NO：11所示的氨基酸序列和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，含有重链可变区的人源化抗人α9整联蛋白抗体由由SEQ ID NO：13所示的氨基酸序列和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，包含由SEQ ID NO：17所示的重链可变区组成的人源化抗人α9整联蛋白抗体由SEQ ID NO：15所示的氨基酸序列和由SEQ ID NO：9所示的氨基酸序列组成的轻链可变区，以及用于预防或治疗涉及人α9整数的各种疾病的手段 rin在发病机制中，其使用抗体。

5. 发明申请

US20110014193A1 HUMANIZED ANTI-HUMAN ALPHA 9-INTEGRIN ANTIBODY 审中-公开
标题翻译：人类抗人ALPHA 9整合抗体
公开(公告)号：US20110014193A1
公开(公告)日：2011-01-20
申请号：US12812368
申请日：2009-07-09
申请人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
发明人： Kenji Uehara , Hirofumi Higuchi , Toshihiro Nakashima , Daisuke Ishikawa , Nobuchika Yamamoto , Hirotada Fujita , Fumihiko Sakai
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04 , C12N15/63 , C12N5/10 , C12P21/06 , A61P19/02
CPC分类号： C07K16/2839 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 1 or the amino acid sequence shown by SEQ ID NO: 1 wherein one or several amino acids are substituted, deleted, inserted and/or added and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 61 or the amino acid sequence shown by SEQ ID NO: 61 wherein one or several amino acids are substituted, deleted, inserted and/or added, as well as a means for preventing or treating various diseases involving human α9 integrin in their pathogenesis, which uses the antibody.
摘要翻译：本发明提供了与供体小鼠抗人α9整联蛋白抗体相比具有改善的活性和/或性质的人源化抗人α9整联蛋白抗体，即人源化抗人α9整联蛋白抗体，其包含由以下组成的重链可变区： SEQ ID NO：1所示的氨基酸序列或SEQ ID NO：1所示的氨基酸序列，其中一个或几个氨基酸被取代，缺失，插入和/或添加，以及由氨基酸组成的轻链可变区 SEQ ID NO：61所示的酸序列或SEQ ID NO：61所示的氨基酸序列，其中一个或几个氨基酸被取代，缺失，插入和/或添加，以及用于预防或治疗涉及人α9整合素在其发病机制中，其使用抗体。

6. 发明申请

US20090053212A1 HUMANIZED ANTI-HUMAN OSTEOPONTIN ANTIBODY 失效
标题翻译：人类抗人类骨质疏松症抗体
公开(公告)号：US20090053212A1
公开(公告)日：2009-02-26
申请号：US11755671
申请日：2007-05-30
申请人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
发明人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
IPC分类号： A61K39/395 , C07K16/18 , C07H21/04 , C12N15/64 , A61P37/06 , C12N1/21 , C12P21/00
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/56
摘要： The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies.
摘要翻译：本发明提供具有比常规的更好的活性（抗原结合活性，白细胞迁移抑制活性等）和/或稳定性（耐热，低pH条件，变性剂等）的人源化抗人骨桥蛋白抗体抗人骨桥蛋白抗体。

7. 发明授权

US07807161B2 Humanized anti-human osteopontin antibody 失效
标题翻译：人源化抗人骨桥蛋白抗体
公开(公告)号：US07807161B2
公开(公告)日：2010-10-05
申请号：US11755671
申请日：2007-05-30
申请人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
发明人： Nobuchika Yamamoto , Fumihiko Sakai , Hirofumi Higuchi , Masaharu Torikai , Toshihiro Nakashima
IPC分类号： A61K39/00 , A61K39/395 , C07K16/46 , C07K16/24
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/56
摘要： The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies.
摘要翻译：本发明提供具有比常规的更好的活性（抗原结合活性，白细胞迁移抑制活性等）和/或稳定性（耐热，低pH条件，变性剂等）的人源化抗人骨桥蛋白抗体抗人骨桥蛋白抗体。

8. 发明授权

US06833353B1 Use of immunosuppressants for MMP mediated diseases 失效
标题翻译：免疫抑制剂用于MMP介导的疾病
公开(公告)号：US06833353B1
公开(公告)日：2004-12-21
申请号：US09786359
申请日：2001-03-14
申请人： Nobuchika Yamamoto , Harumi Yamazaki , Takeshi Ishikawa , Shigeru Johki , Fumihiko Sakai
发明人： Nobuchika Yamamoto , Harumi Yamazaki , Takeshi Ishikawa , Shigeru Johki , Fumihiko Sakai
IPC分类号： A61K3800
CPC分类号： A61K38/13 , A61K31/00 , A61K31/436 , Y10S514/886
摘要： A new use of immunosuppressant for treating or preventing MMp-medicated diseases is provided. The preferred immunosuppresants are tacrolimus, cyclosporing A or 33-epi-chloro-33-desoxyascomycin (pimecrolimus). Particularly, preferable MMP-mediated diseases are the diseases or conditions caused by gelatinase and/or collagenase, and/or inflammatory diseases concerned with gelatinase; such as arthritis (e.g., osteoarthritis, rheumatoid arthritis, etc.) cerebral diseases (e.g., stroke, etc.), tissue ulceration (e.g., corneal, epidermal and gastriculceration, etc.), abnormal wound healing, periodontal diseases, bone diseases (e.g., Paget's diseases, osteoporosis. etc.), tumor growth, tumor metastasis or invasion, HIV-infection, decubitus, decubitis ulcer, restenosis, epidermolysis bullosa, sepsis, septic shock, neoplasm, psoriasis, neovascularization and multiple sclerosis.
摘要翻译：提供了一种新的免疫抑制剂用于治疗或预防MMP药物疾病的新用途。优选的免疫抑制剂是他克莫司，环孢菌素A或33-表氯-3-脱氧菌丝霉素（吡美莫司）。特别地，优选的MMP介导的疾病是由明胶酶和/或胶原酶引起的疾病或病症，和/或与明胶酶相关的炎性疾病; 例如关节炎（例如骨关节炎，类风湿性关节炎等）脑疾病（例如中风等），组织溃疡（例如角膜，表皮和胃溃疡等），异常伤口愈合，牙周病，骨病（例如佩吉特氏病，骨质疏松症等），肿瘤生长，肿瘤转移或侵袭，HIV感染，褥疮，褥疮性溃疡，再狭窄，大疱性表皮松解，败血症，败血性休克，肿瘤，牛皮癣，新生血管形成和多发性硬化。

9. 发明申请

US20110040573A1 Diagnostic System and Method 审中-公开
标题翻译：诊断系统和方法
公开(公告)号：US20110040573A1
公开(公告)日：2011-02-17
申请号：US12900791
申请日：2010-10-08
申请人： Fumihiko Sakai , Minoru Hosoda , Masahiro Kitamura , Toshiyuki Shimizu , Yasuzumi Shimizu , Itsurou Kobayashi , Shinji Kutukake , Hareaki Yamamoto , Yoneyuki Kobayashi , Kouhei Yamashita , Hajime Baba
发明人： Fumihiko Sakai , Minoru Hosoda , Masahiro Kitamura , Toshiyuki Shimizu , Yasuzumi Shimizu , Itsurou Kobayashi , Shinji Kutukake , Hareaki Yamamoto , Yoneyuki Kobayashi , Kouhei Yamashita , Hajime Baba
IPC分类号： G06Q50/00
CPC分类号： A61B5/00 , A61B5/4824 , G06Q50/22 , G06Q50/24 , G16H10/20 , G16H50/20
摘要： A diagnostic system and method. In one embodiment, the invention is a diagnostic system comprising: a form comprising one or more diagnostic questions and one or more possible answers to each diagnostic question; a first overlay comprising one or more windows and one or more diagnostic fields, wherein when the first overlay is positioned over the form, the answers to the diagnostic questions that are indicative of the user having a first medical condition are visible through the windows of the first overlay; and wherein the one or more diagnostic fields contain criteria for diagnosing the user with the first medical condition based on the user's selection of answers on the form that are visible through the windows of the first overlay. In other embodiments, the invention is a computer-based version of the diagnostic system and a diagnostic method.
摘要翻译：诊断系统和方法。在一个实施例中，本发明是一种诊断系统，包括：包括一个或多个诊断问题和每个诊断问题的一个或多个可能答案的形式; 包括一个或多个窗口和一个或多个诊断区域的第一覆盖物，其中当所述第一覆盖层位于所述窗体上方时，对于具有第一医疗状况的用户指示的诊断问题的答案是可见的，第一叠并且其中所述一个或多个诊断字段包含用于基于所述用户对通过所述第一覆盖的窗口可见的表单上的答案的选择来诊断具有所述第一医疗状况的用户的标准。在其他实施例中，本发明是诊断系统的基于计算机的版本和诊断方法。

10. 发明授权

US06673807B1 Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins 失效
标题翻译：免疫抑制咪唑衍生物及其与他克莫司或环孢素的组合制剂
公开(公告)号：US06673807B1
公开(公告)日：2004-01-06
申请号：US09646886
申请日：2000-12-01
申请人： Fumihiko Sakai , Harumi Yamazaki , Noboru Chida , Osamu Nakayama , Yoshihiro Yokota
发明人： Fumihiko Sakai , Harumi Yamazaki , Noboru Chida , Osamu Nakayama , Yoshihiro Yokota
IPC分类号： A61K3144
CPC分类号： A61K31/4439 , A61K31/00 , A61K31/4178
摘要： Methods for increasing graft survival time comprising administering the combination of a compound that inhibits the production of nitric oxide and a compound that is a tricyclic macrolide, such as tacrolimus.
摘要翻译：增加移植物存活时间的方法，包括施用抑制一氧化氮产生的化合物和三环大环内酯的化合物如他克莫司的组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式